NASDAQ:CYNA - CYNA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$40.48
+0.30 (1.20%)
Get New CYNA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYNA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for CYNA in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $40.48.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in CYNA. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2016Janney Montgomery ScottDowngradeBuy ➝ NeutralN/A
i
Rating by Ken Trbovich at Janney Montgomery Scott
8/30/2016Noble FinancialReiterated RatingBuy$50.00N/A
i
8/16/2016BMO Capital MarketsSet Price TargetBuy$30.00N/A
i
Rating by do kim at BMO Capital Markets
7/19/2016BMO Capital MarketsReiterated RatingBuy$21.00N/A
i
Rating by Do Kim at BMO Capital Markets
6/15/2016Janney Montgomery ScottInitiated CoverageBuy$24.00N/A
i
(Data available from 6/14/2016 forward)
CYNA logo
Cynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.
Read More

Today's Range

Now: $40.48
$40.48
$40.48

50 Day Range

MA: N/A

52 Week Range

Now: $40.48
$10.54
$40.67

Volume

N/A

Average Volume

113,889 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CYNA?

The following sell-side analysts have issued reports on CYNA in the last year:
View the latest analyst ratings for CYNA.

What is the current price target for CYNA?

0 Wall Street analysts have set twelve-month price targets for CYNA in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for CYNA in the next year.
View the latest price targets for CYNA.

What is the current consensus analyst rating for CYNA?

CYNA currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CYNA.

How do I contact CYNA's investor relations team?

CYNA's physical mailing address is 828 Richmond St W, TORONTO, ON M6J 1C9, Canada. The biotechnology company's listed phone number is +1-416-7032449. The official website for CYNA is www.cynapsus.ca.